Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database

INTRODUCTION: Bicalutamide (BIC), a non-steroidal anti-androgen, is FDA-indicated for use in combination with a luteinizing hormone-releasing hormone (LHRH) analog for treatment of Stage D2 metastatic carcinoma of the prostate. Lack of consensus exists regarding the clinical benefit of BIC use, eith...

Descripción completa

Detalles Bibliográficos
Autores principales: Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Bylsma, Lauren C., Gillezeau, Christina, Fryzek, Jon, Schultz, Neil M., Flanders, Scott C., Barlev, Arie, Heath, Elisabeth, Quek, Ruben G. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133134/
https://www.ncbi.nlm.nih.gov/pubmed/29946798
http://dx.doi.org/10.1007/s12325-018-0738-5

Ejemplares similares

Ejemplares similares